1-20 of 34
Heidi Greulich
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5610: BAY 2927088: a novel treatment option for patients with NSCLC with HER2 mutations

Franziska Siegel, Kristýna Kotýnková, Gizem Karsli-Uzunbas, Thibaud Jourdan, Melanie Berthold, Stephan Siegel, Daniel Korr, Markus Berger, Haruna Tomono, Sawyer Andersen, Daniel Denney, Jérémie Mortier, Andrew Cherniack, Matthew Meyerson, Heidi Greulich
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 5610.
https://doi.org/10.1158/1538-7445.AM2025-5610
Published: 21 April 2025
View articletitled, Abstract 5610: BAY 2927088: a novel treatment option for patients with NSCLC with HER2 mutations
Journal Articles

Abstract 4035: Preclinical activity of BAY 2927088 in HER2 mutant non-small cell lung cancer

Franziska Siegel, Gizem Karsli-Uzunbas, Kristyna Kotynkova, Quinn McVeigh, Stephan Siegel, Daniel Korr, Volker Schulze, Markus Berger, Georg Beckmann, Andrew Cherniack, Matthew Meyerson, Heidi Greulich
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4035.
https://doi.org/10.1158/1538-7445.AM2023-4035
Published: 04 April 2023
View articletitled, Abstract 4035: Preclinical activity of BAY 2927088 in HER2 mutant non-small cell lung cancer
Journal Articles

Abstract 433: Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Gizem Karsli Uzunbas, Quinn McVeigh, Akansha Gupta, Stephanie Hoyt, Andrew Cherniack, Franziska Siegel, Stephan Siegel, Matthew Meyerson, Heidi Greulich
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 433.
https://doi.org/10.1158/1538-7445.AM2023-433
Published: 04 April 2023
View articletitled, Abstract 433: Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Journal Articles

Abstract 879: SLFN12-mediated depletion of tRNA-Leu-TAA by velcrin treatment induces ribosome pausing at Leu-TTA codons and represses global translation initiation

Stephanie Hoyt, Sooncheol Lee, Joseph McGaunn, Andrew Cherniack, Matthew Meyerson, Heidi Greulich
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 879.
https://doi.org/10.1158/1538-7445.AM2022-879
Published: 15 June 2022
View articletitled, Abstract 879: SLFN12-mediated depletion of tRNA-Leu-TAA by velcrin treatment induces ribosome pausing at Leu-TTA codons and represses global translation initiation
Journal Articles

Abstract 2663: Preclinical profiling of BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy

Silvia Goldoni, Martin Lange, Charlotte Kopitz, Stefan Kaulfuss, Sven Golfier, Adrian Tersteegen, Stefanie Bunse, Melanie Berthold, Thibaud Jordan, Philip Lienau, Franziska Siegel, Annette Walter, Henrik Seidel, Elisa Aquilanti, Andrew Baker, Xiaoyun Wu, Sooncheol Lee, Stefan Gradl, Emmanuelle di Tomaso, Matthew Meyerson, Knut Eis, Ashley Eheim, Heidi Greulich
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2663.
https://doi.org/10.1158/1538-7445.AM2022-2663
Published: 15 June 2022
View articletitled, Abstract 2663: Preclinical profiling of BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy
Journal Articles

Abstract 867: Velcrin-induced cleavage of tRNA-Leu-TAA by SLFN12 RNase causes cancer cell death

Sooncheol Lee, Stephanie Hoyt, Xiaoyun Wu, Colin Garvie, Joseph McGaunn, Andrew D. Cherniack, Matthew Meyerson, Heidi Greulich
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 867.
https://doi.org/10.1158/1538-7445.AM2022-867
Published: 15 June 2022
View articletitled, Abstract 867: Velcrin-induced cleavage of tRNA-Leu-TAA by SLFN12 RNase causes cancer cell death
Journal Articles

Abstract ND04: BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy

Stefan Gradl, Sooncheol Lee, Martin Lange, Xiaoyun Wu, Silvia Goldoni, Timothy Lewis, Charlotte Kopitz, Colin Garvie, Philip Lienau, Stephanie Hoyt, Henrik Seidel, Stephan Kaulfuss, Manuel Ellermann, Luc de Waal, Adrian Tersteegen, Sven Golfier, Detlev Suelzle, Christa Hegele-Hartung, James Carr, Frederick Brookfield, Michael Bruening, Melanie Berthold, Thibaud Jourdan, Monica Schenone, Galen Gao, Joseph McGaunn, Antje Wengner, Elisa Aquilanti, Franziska Siegel, Marine Garrido, Annette Walter, Isabelle Genvresse, Andrew Cherniack, Stuart Schreiber, Knut Eis, Ashley Eheim, Matthew Meyerson, Heidi Greulich
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): ND04.
https://doi.org/10.1158/1538-7445.AM2022-ND04
Published: 15 June 2022
View articletitled, Abstract ND04: BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy
Journal Articles

Abstract 1219: Deep mutational scanning of PDE3A identifies residues required for DNMDP response

Xiaoyun Wu, Malvina Papanastasiou, Gavin Schnitzler, Colin Garvie, Stephanie Hoyt, Terry Zhang, James Mullahoo, Andrew Baker, Joseph McGaunn, Bethany Kaplan, Sooncheol Lee, Martin Lange, Steven Carr, Xiaoping Yang, Federica Piccioni, Andrew Cherniack, Matthew Meyerson, Heidi Greulich
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1219.
https://doi.org/10.1158/1538-7445.AM2021-1219
Published: 01 July 2021
View articletitled, Abstract 1219: Deep mutational scanning of PDE3A identifies residues required for DNMDP response
Journal Articles

Abstract 54: Cryo-EM structure of the PDE3A-SLFN12 complex reveals requirements for the activation of SLFN12 RNase and DNMDP-induced cancer cell killing

Xiaoyun Wu, Colin Garvie, Sooncheol Lee, Steven Horner, Andrew Baker, Marcus Toetzl, Joseph McGaunn, Bethany Kaplan, Luc de Waal, Martin Lange, Timothy Lewis, Chris Lemke, Matthew Meyerson, Heidi Greulich
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 54.
https://doi.org/10.1158/1538-7445.AM2021-54
Published: 01 July 2021
View articletitled, Abstract 54: Cryo-EM structure of the PDE3A-SLFN12 complex reveals requirements for the activation of SLFN12 RNase and DNMDP-induced cancer cell killing
Journal Articles

Abstract 1470: Preclinical activity of the first reversible, potent and selective inhibitor of EGFR exon 20 insertions

Franziska Siegel, Stephan Siegel, Keith Graham, Bethany Kaplan, Kirstin Petersen, Ulf Boemer, Uwe Eberspaecher, Daniel Korr, Ursula Moenning, Detlev Suelzle, Jens Schroeder, Florian Prinz, Sabine Zitzmann-Kolbe, Gizem Karsli-Uzunbas, Timothy Lewis, Mario Hermsen, Andrew Cherniack, Franz von Nussbaum, Knut Eis, Matthew Meyerson, Heidi Greulich
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1470.
https://doi.org/10.1158/1538-7445.AM2021-1470
Published: 01 July 2021
View articletitled, Abstract 1470: Preclinical activity of the first reversible, potent and selective inhibitor of EGFR exon 20 insertions
Journal Articles

Abstract 5880: Small-molecule modulators of PDE3/SLFN12 to kill cancer cells

Timothy A. Lewis, Luc de Waal, Xiaoyun Wu, Manuel Ellerman, Charlotte Kopitz, Antje Wengner, Knut Eis, Martin Lange, Adrian Tersteegen, Philip Lienau, Heidi Greulich, Matthew Meyerson
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5880.
https://doi.org/10.1158/1538-7445.AM2018-5880
Published: 01 July 2018
View articletitled, Abstract 5880: Small-molecule modulators of PDE3/SLFN12 to kill cancer cells
Journal Articles

Abstract 2028: PDE3A modulation for cancer therapy

Xiaoyun Wu, Timothy Lewis, Luc de Waal, Galen Gao, Jian Zhang, Monica Schenone, Colin Garvie, Brett Diamond, Selena Lorrey, Andrew Cherniack, Steven Corsello, Alex Burgin, Todd Golub, Stuart Schreiber, Matthew Meyerson, Heidi Greulich
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2028.
https://doi.org/10.1158/1538-7445.AM2017-2028
Published: 01 July 2017
View articletitled, Abstract 2028: PDE3A modulation for cancer therapy
Journal Articles

Abstract A2: Oncogenic and drug‐sensitive ERBB2 mutations in glioblastoma

Heidi Greulich, Milan Chheda, Tzu‐Hsiu Chen, Kumiko Tanaka, Amit Dutt, Kwok‐Kin Wong, William Hahn, Matthew Meyerson
Journal: Cancer Research
Cancer Res (2009) 69 (23_Supplement): A2.
https://doi.org/10.1158/0008-5472.FBCR09-A2
Published: 28 October 2014
View articletitled, Abstract A2: Oncogenic and drug‐sensitive ERBB2 mutations in glioblastoma
Journal Articles

Abstract 4596: An integrated genomic characterization of the target of a small molecule identifies a novel cancer dependency

Luc M. de Waal, Tim A. Lewis, Lara Gechijian, Aviad Tsherniak, Willmen Youngsaye, Matthew Rees, Oliver Mikse, Mark Hickey, Patrick Faloon, Nicola Tolliday, Angela Koehler, Monica Schenone, Kwok Wong, Alykhan Shamji, Benito Munoz, Stuart L. Schreiber, Heidi Greulich, Matthew L. Meyerson
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 4596.
https://doi.org/10.1158/1538-7445.AM2014-4596
Published: 01 October 2014
View articletitled, Abstract 4596: An integrated genomic characterization of the target of a small molecule identifies a novel cancer dependency
Journal Articles

Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization

Jeonghee Cho, Liang Chen, Naveen Sangji, Takafumi Okabe, Kimio Yonesaka, Joshua M. Francis, Richard J. Flavin, William Johnson, Jihyun Kwon, Soyoung Yu, Heidi Greulich, Bruce E. Johnson, Michael J. Eck, Pasi A. Jänne, Kwok-Kin Wong, Matthew Meyerson
Journal: Cancer Research
Cancer Res (2013) 73 (22): 6770–6779.
https://doi.org/10.1158/0008-5472.CAN-13-1145
Published: 14 November 2013
View articletitled, Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization
Open the PDF for Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization in another window
Includes: Supplementary data
Journal Articles

Abstract 4604: Landscape of human and viral genomic alterations in cervical carcinomas.

Akinyemi I. Ojesina, Lee Lichtenstein, Lauren Ambrogio, Kristian Cibulskis, Samuel Freeman, Chandra Sekhar Pedamallu, Bjørn Bertelsen, Ivan Imaz, Karla Vazquez, Alberto Salido Guadarrama, Victor Treviño, Sandra Romero-Cordoba, Fujiko Duke, Bethany Kaplan, Iram Rodriguez, Magali Espinosa Castilla, Katherine Woie, Line Bjorge, Elisabeth Wik, Mari K. Halle, Erling Høivik, Camilla Krakstad, Gabriela Gómez Macías, María de Lourdes Garza Rodríguez, Jorge Vazquez, Carlos Rodea, Adrian Cravioto, Maria L. Cortes, Heidi Greulich, Christopher P. Crum, Lars Akslen, Hugo Barrera Saldaña, Jorge Melendez-Zajgla, Gad Getz, Helga B. Salvesen, Matthew L. Meyerson
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4604.
https://doi.org/10.1158/1538-7445.AM2013-4604
Published: 15 April 2013
View articletitled, Abstract 4604: Landscape of human and viral genomic alterations in cervical carcinomas.
Journal Articles

Abstract 2: FGFR3 as a therapeutic target in squamous cell lung carcinoma

Rachel Liao, Peter Hammerman, Andrey Sivachenko, Heidi Greulich, Gad Getz, Qingsong Liu, Nathanael Gray, Matthew Meyerson
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2.
https://doi.org/10.1158/1538-7445.AM2012-2
Published: 15 April 2012
View articletitled, Abstract 2: FGFR3 as a therapeutic target in squamous cell lung carcinoma
Journal Articles

Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer

Heidi Greulich, Bethany Kaplan, Philipp Mertins, Tzu-Hsiu Chen, Kumiko Tanaka, Cai-Hong Yun, Marcin Imielinski, Shanatanu Banerji, Michael S. Lawrence, Sarah Walker, Wendy Winckler, Gad Getz, David Frank, Michael Eck, Jacob D. Jaffe, Steven A. Carr, Kwok-Kin Wong, Matthew Meyerson
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 1.
https://doi.org/10.1158/1538-7445.AM2012-1
Published: 15 April 2012
View articletitled, Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer
Journal Articles

Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation

Martin L. Sos, Haridas B. Rode, Stefanie Heynck, Martin Peifer, Florian Fischer, Sabine Klüter, Vijaykumar G. Pawar, Cecile Reuter, Johannes M. Heuckmann, Jonathan Weiss, Lars Ruddigkeit, Matthias Rabiller, Mirjam Koker, Jeffrey R. Simard, Matthäus Getlik, Yuki Yuza, Tzu-Hsiu Chen, Heidi Greulich, Roman K. Thomas, Daniel Rauh
Journal: Cancer Research
Cancer Res (2010) 70 (3): 868–874.
https://doi.org/10.1158/0008-5472.CAN-09-3106
Published: 31 January 2010
View articletitled, Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
Open the PDF for Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation in another window
Includes: Supplementary data
Journal Articles

Abstract #2590: Discovery of EGFR and FGFR2 as therapeutic targets in endometrial cancer

Amit Dutt, Helga Salvesan, Tzu Chen, Heidi Greulich, Matthew Meyerson
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2590.
Published: 01 May 2009
View articletitled, Abstract #2590: Discovery of EGFR and FGFR2 as therapeutic targets in endometrial cancer